Stoke Therapeutics (STOK) News Today → Biden’s $374B Giveaway Into This Sector (From DTI) (Ad) Free STOK Stock Alerts $12.05 +0.40 (+3.43%) (As of 04/19/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineStoke-on-Trent to host its first comedy festivalyahoo.com - April 19 at 8:27 AMStoke City predicted starting XI vs Plymouth as Steven Schumacher weighs up old boys' claimsmsn.com - April 19 at 8:27 AMProtest outside Stoke-on-Trent Crown Court - here's whymsn.com - April 19 at 8:27 AMStoke Therapeutics, Inc. (NASDAQ:STOK) Major Shareholder Sells $41,760,000.00 in Stockinsidertrades.com - April 19 at 6:35 AMStoke Therapeutics (NASDAQ:STOK) Trading 4.5% Higher marketbeat.com - April 18 at 2:47 PMStoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officerfinance.yahoo.com - April 17 at 8:40 AMStoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officerbusinesswire.com - April 17 at 8:00 AMThe focus inside the Stoke City changing room ahead of Plymouth Argyle and 'biggest game of season'msn.com - April 17 at 1:25 AMStoke Therapeutics, Inc. (NASDAQ:STOK) Short Interest Updateamericanbankingnews.com - April 13 at 6:58 AMStoke Therapeutics (NASDAQ:STOK) Stock Rating Reaffirmed by Needham & Company LLCamericanbankingnews.com - April 13 at 6:16 AMStoke Therapeutics, Inc. (NASDAQ:STOK) Forecasted to Earn Q2 2024 Earnings of ($0.43) Per Shareamericanbankingnews.com - April 13 at 2:16 AMResearch Analysts Offer Predictions for Stoke Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:STOK)americanbankingnews.com - April 13 at 1:44 AMStoke Therapeutics Stock (NASDAQ:STOK), Analyst Ratings, Price Targets, Predictionsbenzinga.com - April 12 at 9:48 AMQ2 2024 Earnings Forecast for Stoke Therapeutics, Inc. Issued By Leerink Partnrs (NASDAQ:STOK)marketbeat.com - April 12 at 6:24 AMBuy Rating Justified by Stoke Therapeutics’ Promising Pipeline and Strategic Market Positioningmarkets.businessinsider.com - April 12 at 12:09 AMStoke Therapeutics' (STOK) Buy Rating Reaffirmed at Needham & Company LLCmarketbeat.com - April 11 at 8:32 AMStoke Therapeutics, Inc. Forecasted to Post Q1 2024 Earnings of ($0.54) Per Share (NASDAQ:STOK)marketbeat.com - April 11 at 7:26 AMStoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Recommendation of "Moderate Buy" from Analystsmarketbeat.com - April 6 at 2:43 AMStoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conferencebusinesswire.com - April 4 at 4:30 PMStoke Therapeutics (NASDAQ:STOK) Shares Up 5.1%marketbeat.com - April 4 at 2:24 PMAssessing Stoke Therapeutics: Insights From 6 Financial Analystsmarkets.businessinsider.com - April 4 at 2:16 PMStoke Therapeutics (NASDAQ:STOK) Rating Reiterated by Cantor Fitzgeraldmarketbeat.com - April 4 at 10:16 AMStoke Therapeutics: Positive Dravet Data Sends Shares Soaring, One For The Watchlistseekingalpha.com - April 4 at 1:43 AMStrong Buy Rating for Stoke Therapeutics’ STK-001 Backed by Positive KOL Feedback and Revolutionary Potential in Dravet Syndrome Treatmentmarkets.businessinsider.com - April 3 at 10:41 AMStoke Therapeutics (NASDAQ:STOK) Stock Price Down 9% After Insider Sellingmarketbeat.com - April 2 at 10:27 AMStoke Therapeutics, Inc. (NASDAQ:STOK) General Counsel Sells $67,663.20 in Stockinsidertrades.com - April 2 at 4:26 AMStoke Therapeutics (NASDAQ:STOK) Shares Gap Down to $13.50marketbeat.com - April 1 at 2:00 PMStoke Stock (NASDAQ:STOK) Gains on Drug Update; Is There More Upside Left?msn.com - April 1 at 8:27 AMQ1 2024 Earnings Estimate for Stoke Therapeutics, Inc. (NASDAQ:STOK) Issued By HC Wainwrightmarketbeat.com - March 28 at 8:21 AMStoke Therapeutics Announces Pricing of Upsized $125 Million Public Offeringbusinesswire.com - March 27 at 11:40 PMStoke Therapeutics’ STK-001 Shows Promise: Buy Rating Affirmed Amid Positive Clinical and Financial Outlookmarkets.businessinsider.com - March 27 at 2:39 PMStoke Therapeutics Shares Extend Gains to 52-Week High, Plans for $75M Offeringmarketwatch.com - March 27 at 2:39 PMStoke Therapeutics plans $75M public offering on heels of Dravet trial resultsbizjournals.com - March 27 at 2:39 PMStoke Therapeutics (NASDAQ:STOK) Reaches New 12-Month High After Analyst Upgrademarketbeat.com - March 27 at 10:33 AMWhat's Going On With Stoke Therapeutics Stock Tuesday?msn.com - March 27 at 9:38 AMShares in Bedford-based Stoke Therapeutics surge after encouraging results in studies of epilepsy medicinemsn.com - March 27 at 9:38 AMStoke Therapeutics Announces Proposed Public Offeringbusinesswire.com - March 26 at 4:07 PMTD Cowen ups Stoke to buy on updated data for epilepsy drugmsn.com - March 26 at 12:36 PMStoke stock rockets 73% on updated epilepsy drug datamsn.com - March 26 at 12:36 PMStoke Therapeutics' Anti-Epilepsy Drug Candidate Shows Substantial, Sustained Reductions In Seizure Frequency In Pretreated Patientsfinance.yahoo.com - March 26 at 12:36 PMWedbush Boosts Stoke Therapeutics (NASDAQ:STOK) Price Target to $17.00marketbeat.com - March 26 at 10:46 AMStoke Therapeutics (NASDAQ:STOK) Stock Rating Reaffirmed by HC Wainwrightmarketbeat.com - March 26 at 8:43 AMStoke Therapeutics (NASDAQ:STOK) Stock Rating Upgraded by TD Cowenmarketbeat.com - March 26 at 8:43 AMWhy Is Stoke Therapeutics (STOK) Stock Up 99% Today?investorplace.com - March 26 at 7:54 AMSTOK Stock Earnings: Stoke Therapeutics Beats EPS, Misses Revenue for Q4 2023investorplace.com - March 25 at 10:03 PMStoke stock soars 70% post-market on epilepsy drug datamsn.com - March 25 at 7:21 PMStoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Resultsbusinesswire.com - March 25 at 4:01 PMStoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndromebusinesswire.com - March 25 at 4:01 PMStoke therapeutics executive sells over $14k in company stockinvesting.com - March 21 at 7:33 PMInsider Selling: Stoke Therapeutics, Inc. (NASDAQ:STOK) General Counsel Sells 2,349 Shares of Stockinsidertrades.com - March 20 at 7:48 AM Get Stoke Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for STOK and its competitors with MarketBeat's FREE daily newsletter. Email Address Biden’s $374B Giveaway Into This Sector (Ad)Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here Click here for the full story STOK Media Mentions By Week STOK Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. STOK News Sentiment▼0.570.52▲Average Medical News Sentiment STOK News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. STOK Articles This Week▼164▲STOK Articles Average Week Get Stoke Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for STOK and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: COGT News CELC News WVE News MRSN News DNTH News HRTX News NRIX News CRBP News STTK News GRCL News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:STOK) was last updated on 4/19/2024 by MarketBeat.com Staff From Our PartnersThe “Perfect Storm” for GoldGold Safe ExchangeBiden’s $374B Giveaway Into This SectorDTISHOCKING Crypto Leak…Crypto 101 MediaHe Is Giving Away BitcoinCrypto Swap ProfitsThe #1 Crypto for 2024InvestorPlaceOptions trading has suddenly become more reliable.Eagle PublishingHow Biden has already won 2024Porter & CompanyTop 5 AI Stocks to Buy for 2024Market Moving Trends Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stoke Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.